#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Infections caused by respiratory syncytial viruses – epidemiology, clinical picture, diagnosis, prevention and treatment options


Authors: Hubáček Petr 1;  Smíšková Dita 2
Authors place of work: Ústav lékařské mikrobiologie, 2. lékařská fakulta Univerzity Karlovy a FN Motol, Praha 1;  Klinika infekčních nemocí, 2. lékařská fakulta Univerzity Karlovy a FN Bulovka, Praha 2
Published in the journal: Čes-slov Pediat 2023; 78 (Supplementum 1): 13-19.
Category: Comprehensive Report
doi: https://doi.org/10.55095/CSPediatrie2023/027

Summary

Respiratory syncytial virus (RSV) is important cause of morbidity, especially in early childhood. In the article, we summary the improvement and changes either in understanding of RSV patofysiology, it’s acute and long term effects, same as in diagnostics, therapy or prevention.

Keywords:

Asthma – Respiratory syncytial virus – respiratory infection – ribavirine – palivizumab


Zdroje

1. Buchholz UJ, Anderson LJ, Collins PL, Mejias A. Respiratory syncytial virus and metapneumovirus. In: Howley PM, Knipe DM (eds.). Field’s Virology - Volume 3: RNA viruses. Philadelphia: Wolters Kluwer 2023: 267–317.

2. Borchers AT , Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus-- a comprehensive review. Clin Rev Allergy Immunol 2013; 45: 331–379.

3. Bohmwald K, et al. Contribution of Cytokines to Tissue Damage During Human Respiratory Syncytial Virus Infection. Front Immunol 2019; 10: 452.

4. Bergeron HC, Tripp RA. RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein. Viruses 2022; 14.

5. S traňák Z. Imunoprofylaxe závažných forem RSV infekce neovlivňuje očkování u dětí – nová indikační kritéria. Pediatr praxi 2015; 16: 247–250.

6. M unywoki PK, et al. Influence of age, severity of infection, and co-infection on the duration of respiratory syncytial virus (RSV) shedding. Epidemiol Inf 2015; 143: 804–812.

7. K ombe IK, Munywoki PK, Baguelin M, et al. Model-based estimates of transmission of respiratory syncytial virus within households. Epidemics 2019; 27: 1–11.

8. Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on prevention strategies. Human Vaccines Immunother 2018; 14: 234–244.

9. O bando-Pacheco P, et al. Respiratory Syncytial Virus Seasonality: A Global Overview. J Inf Dis 2018; 217: 1356–1364.

10. H artert TV, Ortiz JR. Need for improved global measurement of early childhood respiratory syncytial virus disease. Lancet 2022; 399: 1993–1995.

11. P ratt MTG, et al. Prevalence of respiratory viruses in community-acquired pneumonia in children: a systematic review and meta-analysis. Lancet 2022; 6: 555–570.

12. Vazquez Y, et al. Cytokines in the Respiratory Airway as Biomarkers of Severity and Prognosis for Respiratory Syncytial Virus Infection: An Update. Front Immunol 2019; 10: 1154.

13. M anti S, Piedimonte G. An overview on the RSV-mediated mechanisms in the onset of non-allergic asthma. Front Pediatr 2022; 10: 998296.

14. Wennergren G, Kristjansson S. Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases. Eur Resp J 2001; 18: 1044–1058.

15. H on KL, Leung AKC, Wong AHC, et al. Respiratory Syncytial Virus is the Most Common Causative Agent of Viral Bronchiolitis in Young Children: An Updated Review. Curr Ped Rev 2023; 19: 139–149.

16. R uiz S, Calvo C, Pozo F, et al. Lung function, allergic sensitization and asthma in school-aged children after viral-coinfection bronchiolitis. Sci Reports 2022; 12: 7552.

17. L iu D, et al. miR-34b/c-5p/CXCL10 Axis Induced by RSV Infection Mediates a Mechanism of Airway Hyperresponsive Diseases. Biology 2023; 12.

18. L ong X, et al. IL-17A plays a critical role in RSV infection in children and mice. Virology J 2023; 20: 30.

19. P ischedda S, et al. Role and Diagnostic Performance of Host Epigenome in Respiratory Morbidity after RSV Infection: The EPIRESVi Study. Front Immunol 2022; 13: 875691.

20. Chirkova T, et al. Effect of Infant RSV Infection on Memory T Cell Responses at Age 2-3 Years. Front Immunol 2022; 13: 826666.

21. Backman K, Ollikainen H, Piippo-Savolainen E, et al. Asthma and lung function in adulthood after a viral wheezing episode in early childhood. Clin Experiment Allergy 2018; 48: 138–146.

22. P oulsen A, et al. Long-term consequences of respiratory syncytial virus acute lower respiratory tract infection in early childhood in Guinea-bissau. Pediatric Inf Dis J 2006; 25: 1025–1031.

23. M iller EK, et al. Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatric Inf Dis J 2013; 32: 950–955.

24. F lorin TA , Plint AC, Zorc JJ. Viral bronchiolitis. Lancet 2017; 389: 211–224.

25. E isenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection--a systematic review. Crit Care 2006; 10: R107.

26. E rez DL, et al. Apnea induced by respiratory syncytial virus infection is not associated with viral invasion of the central nervous system. Pediatric Inf Dis J 2014; 33, 880–881.

27. R alston S, Hill V. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatrics 2009; 155: 728–733.

28. K hiabani K, Amirzade-Iranaq MH. Are saliva and deep throat sputum as reliable as common respiratory specimens for SARS-CoV-2 detection? A systematic review and meta-analysis. Am J Infection Control 2021; 49: 1165–1176.

29. Warren TK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531: 381–385.

30. Jung BK, Choi SH, Lee JH, et al. Performance evaluation of four rapid antigen tests for the detection of Respiratory syncytial virus. J Med Virol 2016; 88: 1720–1724.

31. L eonardi GP, Wilson AM, Dauz M, Zuretti AR. Evaluation of respiratory syncytial virus (RSV) direct antigen detection assays for use in point-of-care testing. J Virol Methods 2015; 213: 131–134.

32. Walsh P, et al. Is the interpretation of rapid antigen testing for respiratory syncytial virus as simple as positive or negative? Emergency medicine journal : EMJ 2014; 31: 153–159.

33. N eopane P, Nypaver J, Shrestha R, Beqaj S. Performance Evaluation of TaqMan SARS-CoV-2, Flu A/B, RSV RT-PCR Multiplex Assay for the Detection of Respiratory Viruses. Inf Drug Resistance 2022; 15: 5411– 5423.

34. Y un J, et al. Evaluation of Three Multiplex Real-time Reverse Transcription PCR Assays for Simultaneous Detection of SARS-CoV-2, Influenza A/B, and Respiratory Syncytial Virus in Nasopharyngeal Swabs. J Korean Med Sci 2021; 36: e328.

35. Quinton M, Geahr M, Gluck L, et al. Evaluation of the respiratory NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage and Alinity m Resp-4-Plex assays. J Clin Virol 2022; 150–151.

36. T rang TP, Whalen M, Hilts-Horeczko A, et al. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature. Transplant Inf Dis 2018; 20: e12844.

37. Beaird OE, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transplant Inf Dis 2016; 18: 210–215.

38. H irsch HH, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Inf Dis 2013; 56: 258–266.

39. M alin JJ, Suarez I, Priesner V, et al. Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev 2020; 34.

40. T ian L, et al. Molnupiravir and Its Antiviral Activity Against COVID-19. Front Immunol 2022; 13: 855496.

41. H olman W, et al. Accelerated first-in-human clinical trial of EIDD-2801/MK- 4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2. Trials 2021; 22: 561.

42. F uruta Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002; 46: 977–981.

43. S kjerven HO, et al. Racemic adrenaline and inhalation strategies in acute bronchiolitis. NEJM 2013; 368: 2286–2293.

44. R alston SL, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014; 134: e1474– 1502.

45. D elgado MF, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nature Med 2009; 15: 34–41.

46. K im HW, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89: 422–434.

47. G riffiths C, Drews SJ, Marchant DJ. Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev 2017; 30: 277–319.

48. M azur NI, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet. Infectious diseases 2018; 18: e295–e311.

Štítky
Neonatology Paediatrics General practitioner for children and adolescents
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#